| Name | Title | Contact Details |
|---|
Fifth Eye`s early warning system continuously forecasts patient trajectory, giving doctors and nurses a heads up about impending trouble hours in advance of other methods.
Governance Institute, The is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diversified Group Administrators is a Harrisburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ophelia is a digital provider of medication-assisted treatment (MAT) for opioid use disorder (OUD), committed to making evidence-based treatment universally accessible. Its mission is to remove barriers for the 80% of Americans with OUD who are unable to access care and the 50,000+ MAT-licensed clinicians who are unable to treat patients due to a lack of infrastructure, training, and support. At its core is the Ophelia Care Model, a team-based clinical model and software platform developed by leading experts in addiction medicine and psychiatry. Ophelia is licensed to provide care in 36 states and contracted with Medicaid, Medicare, and Commercial insurers covering 85 million American lives.
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and medical technologies for infusion, transfusion and clinical nutrition. Our expansive portfolio of products and global network of science and manufacturing centers provide essential support for the care of critical and chronically ill patients. We are part of Fresenius SE, a health care group with more than 100 years of experience in pharmaceuticals, medical devices and life sciences. Our employees – more than 35,000 worldwide – develop and deliver injectable pharmaceuticals and infusion systems; blood collection, transfusion and cell technologies; and essential nutrients for parenteral nutrition. We have special expertise in medicines for oncology, infection, anesthesia, analgesia and critical care. Our products are used in all sites of care – from hospitals and clinics to blood and plasma centers, and increasingly in patients’ homes. In biosimilars, we are developing products with a focus on oncology and autoimmune diseases.